Arrow Greentech Q1 FY27: High Tech Segment Powers A Step-Change Quarter

Arrow Greentech reported a sharp step-up in profitability in Q1 FY27, driven almost entirely by its High Tech Product segment. Revenue from operations came in at Rs 878 million, up 111 percent year on year and 110 percent sequentially. Operating leverage was visible in margins. EBITDA rose to Rs 359 million and the EBITDA margin expanded to 40.9 percent. Profit after tax increased to Rs 274 million, taking the PAT margin to 30.5 percent.

Management described Q1 FY27 as a defining quarter, saying the performance reflected the commercial conversion of several years of investment in capacity, research and development, and patents. The commentary also highlighted the company’s focus on anti-counterfeit solutions and high-value security applications, while acknowledging that the Green Products segment continues to track underlying demand cycles.

Segment mix explains the quarter

The reported segment split shows a clear divergence between the two operating segments. High Tech Products delivered Rs 816 million of revenue in Q1 FY27, up 137 percent year on year and 135 percent quarter on quarter. In contrast, Green Products revenue was Rs 63 million, down 12 percent both year on year and sequentially.

This mix shift matters because it coincided with a large margin expansion. While the presentation does not disclose segment margins, the consolidated results show EBITDA margin rising from 24.8 percent in Q4 FY26 to 40.9 percent in Q1 FY27. With finance cost at Rs 1 million, most of the operating improvement flowed through to profit before tax and PAT.

Financial summary (Consolidated, Rs million)

What drove profitability

The consolidated profit and loss statement shows raw material cost structure improving in Q1 FY27 in tandem with scale. Total raw material cost was reported at Rs 398 million on revenue of Rs 878 million, translating into a gross margin of 54.7 percent. The gross margin itself was broadly stable compared to Q4 FY26 (55.5 percent), but the step-up in EBITDA margin indicates tighter control over operating expenses and benefits of scale.

Employee expenses were Rs 47 million, broadly flat versus Q4 FY26, while other expenses were Rs 75 million, lower than Rs 82 million in Q4 FY26 despite the sharp revenue increase. Depreciation declined to Rs 16 million from Rs 20 million in Q4 FY26. Other income was Rs 21 million.

The result was an EBIT of Rs 364 million and profit before tax of Rs 363 million. Tax for the quarter was Rs 88 million.

Business overview: green materials, security products, and IP

The presentation positions Arrow Greentech across multiple verticals.

In Water Soluble Films, the company’s flagship brand Watersol is described as a range of water-soluble packaging films made from polyvinyl alcohol that dissolve fully in water. The film is described as having high strength and tear resistance and being used across packaging, healthcare, agriculture, textiles and consumer goods applications. The company also describes itself as the largest manufacturer of water soluble films in India and highlights a manufacturing facility at Ankleshwar, Gujarat, with an in-house R and D centre.

In Security Products, the company highlights manufacturing of anti-counterfeit products for use in high security papers and brand protection, with proprietary technology and an in-house R and D centre. Management commentary attributes the quarter’s strong performance to deepening commitment to anti-counterfeit solutions and capturing opportunities in high-value security applications.

The Intellectual Property section is a core pillar of the narrative. The presentation states that Arrow has obtained more than 50 patents globally, with 21 presently in-force across territories including India, the UK, the USA, Europe, Sri Lanka and Malaysia. It also mentions 41 registered trademarks in India and additional patent and trademark applications under process.

Arrow RX and Avery Pharmaceuticals

Avery Pharmaceuticals, described as a wholly owned subsidiary, is presented as a platform business focused on mouth dissolving strips using embedded water-soluble film technology. The presentation states that the Sanand facility is WHO GMP approved and carries certifications including FSSAI, GLP, ISO 9001 and ISO 22000.

On approvals, the presentation states that product approvals have been received for around 50 products, and separately notes over 54 products approved under FSSAI and more than 10 products under prescription approval. It also states that the company is in discussion with domestic and international companies for long-term supply contracts, has entered contracts with domestic and international MNC companies, is pursuing product registrations in countries such as Russia, Yemen and Vietnam, and is engaged in CDMO projects.

The deck also lists multiple FSSAI and Rx approved products, including nutraceutical strips such as Vitamin D3 and Vitamin B12, and prescription products such as Nicotine Polacrilex, Ondansetron, Sildenafil and Amlodipine among others.

What to track from here

The Q1 FY27 numbers show that the company can scale profitability when the High Tech Product segment performs strongly. At the same time, the Green Products segment declined again, and the presentation itself notes it follows underlying demand cycles. This keeps the segment mix and sustainability of margin levels as key monitoring points.

Management’s forward commentary remains qualitative. The company said it will continue to invest in its product portfolio and explore environmentally sustainable innovations that can be integrated into operations during the balance of FY 2026 to 27. Given the sharp quarter-on-quarter jump and the dependence on High Tech Products for growth, investors will likely focus on whether the security products momentum can be sustained and whether the Green Products segment stabilizes.

Key takeaways

Arrow Greentech’s Q1 FY27 performance was defined by a surge in High Tech Products revenue to Rs 816 million, which pushed consolidated revenue to Rs 878 million and delivered a sharp improvement in margins. The company continues to position itself around a combination of water-soluble film manufacturing, security products, and a sizable IP portfolio, while also building Avery Pharmaceuticals around mouth dissolving strips and CDMO opportunities. The next few quarters should clarify how durable the High Tech growth is and whether the Green Products segment can return to growth.